Therapeutic KCNK9 Antibody
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Breast cancer, gastric cancer, lung cancer (KCNK9-overexpressing tumors)
Modality
Monoclonal Antibody
Mechanism
KCNK9 ion channel inhibitor (antibody)
Target
KCNK9
rNPV Envelope
Low
-$50.7M
costs +25% · peak −25%
Base
-$23.8M
cumulative PoS 3.8%
High
$3.2M
costs −25% · peak +25%
Costs follow naked-biologic CMC norms with a biomarker-stratified (KCNK9-overexpression-selected) Phase 2/3 that is smaller than an all-comers oncology program, anchored to the Elahere FRα-stratified ovarian pathway and Herceptin's over-expression-defined breast development. Phase 1 PoS uses oncology-mAb baselines; Phase 2 is held below BIO/QLS oncology-biologic levels with an explicit downward adjustment because targeting an ion-channel cap-domain epitope for tumor cytotoxicity is mechanistically unprecedented in an approved drug and proof-of-concept in patients carries elevated translational risk beyond the Nature Communications 2016 xenograft/metastasis data. Phase 3 PoS reflects biomarker-stratified oncology-antibody precedent, kept under the buoyant Phase-1 number so cumulative loss-of-approval lands in the single-digit-percent band.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.70
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.584 — composite-score rank #37 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#16) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Herceptin (Genentech/Roche) — trastuzumab
Closest mechanism analogue: a naked humanized IgG1 directed against a cell-surface protein over-expressed on ~15-20% of breast tumors, acting through receptor engagement plus ADCC/immune-dependent cytotoxicity — the exact therapeutic logic the KCNK9 mAb proposes (target an over-expressed surface epitope in a marker-defined breast/gastric subset). Establishes that an over-expression-stratified naked anti-surface-protein mAb can reach blockbuster scale in breast and gastric cancer.
Criteria 2 and 4: launched naked-mAb breast/gastric comparator that is the canonical over-expression-stratified surface-target precedent; pre-biosimilar peak anchors the naked-mAb breast/gastric revenue ceiling.
Elahere (AbbVie/ImmunoGen) — mirvetuximab soravtansine-gynx
Cleanest biomarker-defined, biologic-based oncology comparator: FRα-directed antibody therapeutic approved (accelerated Nov-2022, full Mar-2024) only in the FRα-expressing platinum-resistant ovarian subset on a companion-diagnostic. Mirrors this asset's strongest indication — ovarian cancer, where KCNK9 is over-expressed in >90% of tumors — and frames the marker-stratified ovarian regulatory/commercial pathway and a realistic biomarker-restricted launch trajectory.
Criteria 2 and 3: launched biomarker-stratified antibody-based ovarian comparator anchoring companion-diagnostic regulatory design and a marker-restricted ramp; ~$0.5B+ annualized run-rate within first full year sets a conservative biomarker-defined-mAb peak band.
Enhertu (Daiichi Sankyo/AstraZeneca) — trastuzumab deruxtecan
Upper-bound benchmark for an antibody-based agent directed at an over-expressed antigen in breast and gastric cancer; ~$2.9B 2024 sales (Daiichi-reported) defines the realistic ceiling for a successful breast/gastric surface-target antibody franchise. Used only as a ceiling — it is an antibody-drug conjugate with a cytotoxic payload, not a naked mAb, so it overstates what an unconjugated KCNK9 mAb would earn.
Criteria 2 and 4: launched breast/gastric antibody-based comparator setting the franchise revenue ceiling; flagged as an ADC, not a naked mAb, so it bounds rather than predicts this asset's peak.
ML308 (NIH Molecular Libraries KCNK9 probe)
Same-target tool comparator, not a clinical competitor: ML308 is a selective small-molecule KCNK9 inhibitor (IC50 ~130 nM) developed under the NIH Molecular Libraries Program as a research probe. It confirms KCNK9 is a chemically tractable but clinically undeveloped target — no KCNK9-directed therapeutic has entered the clinic — supporting the first-in-clinic framing while showing the target has been probed for over a decade without a drug.
Criteria 1: same molecular target (KCNK9) but a non-clinical chemical probe; provides target-tractability and competitive-vacuum context, not a revenue anchor.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $16.0M | 24 mo | 45.0% | [0] [1] [5] |
| Phase I | $55.0M | 18 mo | 60.0% | [1] [2] [5] |
| Phase II | $150.0M | 30 mo | 32.0% | [2] [3] [4] |
| Phase III | $330.0M | 42 mo | 52.0% | [3] [4] |
| NDA/BLA Review | $16.0M | 12 mo | 85.0% | [3] [4] |
Multiplier handling: Eligible multipliers (genetic_validation_2.6x, biomarker_1.7x) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$900.0M peak · WACC 13.0%
Peak revenue. KCNK9 is over-expressed in ~40% of breast, ~30% of lung, and >90% of ovarian tumors, so a companion-diagnostic-selected addressable population across a lead solid-tumor indication plus expansion is on the order of low-hundreds-of-thousands of patients globally. Benchmarked between Elahere's biomarker-restricted ovarian trajectory (~$0.5B+ first-full-year run-rate, conservative near-term ceiling for a marker-defined launch) and Herceptin's over-expression-defined breast scale, a successful naked anti-KCNK9 mAb launching into one biomarker-defined subset with measured expansion supports a ~$0.9B risk-unadjusted peak — deliberately below Enhertu's ~$2.9B because that is a payload-bearing ADC across multiple settled indications whereas this is an unconjugated single-mechanism antibody whose monotherapy effect size in patients is unproven.
WACC. An oncology antibody in a biomarker-stratified solid-tumor subset is a mainstream pharma category (12%), but engaging an ion-channel cap-domain epitope for tumor-cell cytotoxicity is an unprecedented therapeutic mechanism with no clinical precedent for any KCNK9-directed agent, so 13% sits one notch above standard oncology-mAb risk.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$23.8M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$207.3M
P25
-$70.6M
P50 (median)
-$19.0M
P75
-$10.5M
P95
-$5.3M
Prob ≥ 0
2.8%
Comparable launch curves
Revenue trajectories of named comparators
Herceptin (Genentech/Roche) — trastuzumab
Launched 1998 · peak $6.65B (estimated)
Evidence register
7 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
KCNK9 is the oncogene at the 8q24.3 breast-cancer amplicon (target genetic validation) multipliers_rationale | Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene peer_review | 2003-04-01 | high |
Anti-KCNK9 extracellular-domain mAb (Y4) inhibits tumor growth and metastasis — mechanism feasibility stage_profile.preclinical.pos | A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis peer_review | 2016-02-08 | high |
K2P channels have a large structured extracellular cap domain (antibody-accessible epitope) stage_profile.phase_2.pos | Structures of TASK-1 and TASK-3 K2P channels provide insight into their gating and dysfunction in disease peer_review | 2024-08-05 | medium |
KCNK9 is a clinically undeveloped target — only research-probe small molecules exist (first-in-clinic context) comparators[3] | Development of a Selective Chemical Inhibitor for the Two-Pore Potassium Channel, KCNK9 (ML308) — NIH Molecular Libraries Probe Report peer_review | 2013-03-07 | high |
Elahere biomarker-stratified ovarian antibody-therapeutic regulatory + early-revenue anchor comparators[1].peak_revenue_usd | FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant epithelial ovarian cancer regulatory | 2022-11-14 | high |
KCNK9 imprinting dysregulation in triple-negative breast cancer (indication breadth + biomarker) peak_revenue_usd | Epigenetic Dysregulation of KCNK9 Imprinting and Triple-Negative Breast Cancer peer_review | 2021-11-30 | medium |
KCNK gene over-expression correlates with poor breast-cancer survival (unmet-need / peak framing) peak_revenue_usd | Integrative Analysis of KCNK Genes and Establishment of a Specific Prognostic Signature for Breast Cancer peer_review | 2022-05-12 | medium |
Thesis
Why this asset earns its rank
This is a genuine therapeutic asset: a humanized monoclonal antibody (patent US-2023-0220067, Hopkins/Maryland/Kennedy Krieger, JHTV case C16217) directed against the extracellular domain of KCNK9 (TASK-3), a two-pore-domain potassium channel that is the sole over-expressed gene at the recurrently amplified 8q24.3 amplicon and a validated oncogene conferring hypoxia and serum-deprivation resistance (Mu 2003). The mechanistic question a CMO will raise first — can a conventional IgG functionally engage an ion channel, whose extracellular loops are usually tiny — has an asset-specific answer: K2P channels are atypical in carrying a large structured extracellular cap domain over the ion pathway, and the founding Nature Communications 2016 study showed an anti-extracellular-domain mAb (Y4) induces channel internalization, kills KCNK9-expressing carcinoma cells, and suppresses lung-xenograft growth and breast-cancer metastasis via cell-autonomous and immune-dependent cytotoxicity. This is mechanistically unprecedented for an approved drug and is the central translational risk, not a settled fact.
Economically the asset is anchored to surface-target oncology antibodies. Herceptin establishes that a naked IgG against an over-expressed surface protein in a marker-defined breast/gastric population can reach blockbuster scale, and Elahere frames the realistic biomarker-stratified path — a companion-diagnostic-restricted antibody therapeutic in the KCNK9-rich ovarian setting (>90% over-expression) with a measured first-year ramp — while Enhertu bounds the franchise ceiling as an ADC, not a naked mAb. The engine result is -$50.7M to $3.2M, with a base rNPV of -$23.8M and cumulative PoS of 3.8%; that spread says the case is real but mechanism-defensibility-heavy, hinging on whether cap-domain engagement produces a monotherapy effect size in patients rather than only in 2016 mouse models.
Verdict: a credible, mechanism-risk-loaded oncology antibody worth a conversation. It earns its rubric rank on clinical relevance (validated oncogenic target across breast/lung/ovarian), high IRA exposure for an oncology biologic, and a neutral whitespace score — not on de-risked clinical data. It is vc_fundable because the target genetics and the published proof-of-concept antibody support a standard biotech equity path, conditional on a biomarker-tight first indication.
Key risks
Asset-specific, not generic biotech risks
- Mechanism-feasibility risk: targeting an ion-channel cap-domain epitope for tumor-cell cytotoxicity has no approved-drug precedent; the effect depends on antibody-induced channel internalization and immune-dependent killing demonstrated only in Nature Communications 2016 xenograft/metastasis models, and human monotherapy effect size is unproven.
- First-in-clinic / undrugged-target risk: no KCNK9-directed therapeutic has ever entered the clinic; the only same-target agents are research-grade small-molecule probes (e.g. NIH ML308), so there is no clinical precedent, no validated biomarker assay, and no regulatory template specific to KCNK9.
- Selectivity and on-target safety: KCNK9 (TASK-3) is expressed in neurons (KCNK9 loss causes Birk-Barel intellectual-disability syndrome); a systemically dosed channel-engaging antibody must demonstrate tumor-selective activity and an acceptable CNS/cardio-respiratory safety margin given TASK-channel physiology.
- Companion-diagnostic dependence: the value case rests on a KCNK9-over-expression selection assay (IHC/CNV) that does not yet exist as a validated companion diagnostic; Elahere's FRα-assay history shows marker-assay development can gate both trial enrollment and label.
- Stage risk: the asset is preclinical and 'ready for corporate partnership' (RoI 2020, web-published 2025) with data only available on request; the rubric rank reflects target validation and modality, not de-risked clinical evidence, and timelines to a first-in-human study are still front-loaded.